A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- Australian study probes how genetic variants combine to cause MS
- This MS advocate has turned her weakness into strength
- How I became an advocate for young people with MS
- Starting at age 8, MS has been the invisible illness invading my life
- ‘Molecular atlas’ uses military blood samples to spot disease years early